2018
Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection
Rentsch CT, Cartwright EJ, Gandhi NR, Brown ST, Rodriguez-Barradas MC, Goetz MB, Marconi VC, Gibert CL, Re VL, Fiellin DA, Justice AC, Tate JP. Provider verification of electronic health record receipt and nonreceipt of direct-acting antivirals for the treatment of hepatitis C virus infection. Annals Of Epidemiology 2018, 28: 808-811. PMID: 30195616, PMCID: PMC6318448, DOI: 10.1016/j.annepidem.2018.08.007.Peer-Reviewed Original ResearchConceptsHepatitis C virus infectionCorporate Data WarehouseChronic HCV infectionC virus infectionPositive predictive valuePredictive valueHCV infectionHCV treatmentVirus infectionVeterans Health Administration Corporate Data WarehouseChronic hepatitis C virus (HCV) infectionStudy periodModern treatment eraRetrospective cohort studyElectronic health record dataPharmacy fill recordsHealth record dataNegative predictive valueElectronic health recordsAntiviral regimenHCV therapyTreatment eraChart reviewCohort studyAntiviral treatment
2016
Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras
Klein MB, Althoff KN, Jing Y, Lau B, Kitahata M, Re V, Kirk GD, Hull M, Kim HN, Sebastiani G, Moodie EE, Silverberg MJ, Sterling TR, Thorne JE, Cescon A, Napravnik S, Eron J, Gill MJ, Justice A, Peters MG, Goedert JJ, Mayor A, Thio CL, Cachay ER, Moore R, Research and Design of IeDEA F, Kirk G, Benson C, Bosch R, Boswell S, Mayer K, Grasso C, Hogg R, Harrigan P, Montaner J, Cescon A, Samji H, Brooks J, Buchacz K, Gebo K, Moore R, Moore R, Rodriguez B, Horberg M, Silverberg M, Thorne J, Goedert J, Jacobsonc L, D'Souza G, Klein M, Rourke S, Burchell A, Rachlis A, Hunter-Mellado R, Mayor A, Gill M, Deeks S, Martin J, Patel P, Brooks J, Saag M, Mugavero M, Willig J, Eron J, Napravnik S, Kitahata M, Crane H, Kim H, Drozd D, Sterling T, Haas D, Bebawy S, Turner M, Justice A, Dubrow R, Fiellin D, Gange S, Anastos K, Moore R, Saag M, Gange S, Kitahata M, Althoff K, McKaig R, Justice A, Freeman A, Moore R, Freeman A, Lent C, Kitahata M, Van Rompaey S, Crane H, Drozd D, Morton L, McReynolds J, Lober W, Gange S, Althoff K, Abraham A, Lau B, Zhang J, Jing J, Golub E, Modur S, Wong C, Hogan B, Tong W, Liu B. Risk of End-Stage Liver Disease in HIV-Viral Hepatitis Coinfected Persons in North America From the Early to Modern Antiretroviral Therapy Eras. Clinical Infectious Diseases 2016, 63: 1160-1167. PMID: 27506682, PMCID: PMC5064164, DOI: 10.1093/cid/ciw531.Peer-Reviewed Original ResearchConceptsEnd-stage liver diseaseUse of antiretroviralsESLD riskAntiretroviral therapyLiver diseaseNorth American AIDS Cohort CollaborationTime-updated CD4 cell countModern antiretroviral therapy (ART) eraAntiretroviral therapy eraTenofovir-based regimensCD4 cell countModern antiretroviral therapyHuman immunodeficiency virusIncidence rate ratiosRate ratioCohort CollaborationCoinfected PersonsTherapy eraHCV therapyHIV RNAHepatitis BHepatitis statusImmunodeficiency virusC virusAntiretroviral era